A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages

  Cohen, Ricardo Vitor ^a   Neto, Manoel Galvão ^b   Correa, Jose Luis ^a   Sakai, Paulo ^a   Martins, Bruno ^a   Schiavon, Carlos Aurélio ^a   Petry, Tarissa ^a   Salles, Joao Eduardo ^a   Mamedio, Cristina ^a   Sorli, Christopher ^c  

^a Oswaldo Cruz German Hospital   (Brazil)

^b Gastro Obeso Center   (Brazil)

^c Billings Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIPID;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; DIGESTIVE SURGICAL DEVICE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OBESITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SAFETY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH BYPASS; THERAPY EFFECT; WEIGHT CHANGE;

ADOLESCENT; ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DUODENUM; FEMALE; GASTRIC BYPASS; GLUCOSE; HUMANS; JEJUNUM; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873616035     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2814     Document Type: Article

References (18)

1. Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, shamcontrolled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71:976-982.
2. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the Endo Barrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251: 236-243.
3. de Moura EG, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14:183-189.
4. Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11:725-732.
5. Levine A, Ramos A, Escalona A, et al. Radiographic appearance of endoscopic duodenal-jejunal bypass liner for treatment of obesity and type 2 diabetes. Surg Obes Relat Dis. 2009;5:371-374.
6. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg. 2010;21:351-355.
7. Hussain A, Mahmood H, El-Hasani S. Can Roux-en-Y gastric bypass provide a lifelong solution for diabetes mellitus? Can J Surg. 2009;52:E269-E275.
8. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002;236:554-559.
9. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-242.
10. Basso N, Capoccia D, Rizzello M, et al. First-phase insulin secretion, insulin sensitivity, ghrelin, glucagon-like peptide-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis. Surg Endosc. 2011;25:3540-3550.
11. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567-1576.
12. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Arq Bras Endocrinol Metabol. 2011;55:367-382.
13. Reis CE, Alvarez-Leite JI, Bressan J, Alfenas RC. Role of bariatricmetabolic surgery in the treatment of obese type 2 diabetes with body mass index<35 kg/m(2): a literature review. Diabetes Technol Ther. 2012;14:1-8.
14. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
15. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945-1954.
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
17. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found. 1983;64:3-9.
18. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679.